Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, will present new data supporting GJB2-GT program candidate selection to address hearing loss related to mutations in the GJB2 gene during the Company’s R&D Day taking place , Thursday, April 6, 2023.
